

# PACE/PAP PROVIDER BULLETIN

May 8, 2024

## UPDATE: Coverage changes to GlaxoSmithKline (GSK) Inhalers

**Effective June 12, 2024**

### **Addition of Medical Exception criteria and non-PAR status to the following GSK Branded Inhalers beginning June 12, 2024:**

- 1. The program will implement the following medical exception criteria:**
  - **Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Trelegy Ellipta and Serevent Diskus:** Only covered for diagnosis of COPD.
  - Medical exception documentation must be sent by the prescriber and approved by PACE for payment.
  - Please note: Any claims submitted as OCC-2 for the above medications will continue to pay without requirement of an approved medical exception.
- 2. The following medications convert to non-PAR and will no longer be covered by the program:**
  - Arnuity Ellipta
  - Ventolin HFA
  - Advair HFA/Diskus and Flovent HFA/Diskus

**PAR manufacturers with PACE are not affected by this change.**

Correspondence will notify prescribers that PACE is implementing these changes for the above-mentioned medications, and that they may need to consider alternative therapies or complete medical exception paperwork for their patients, as applicable.

GSK offers programs for patients that meet income and other eligibility criteria requirements. Members of the PACE, PACENET, and PAP Programs that are affected by these changes should access GSK for you ([www.gskforyou.com](http://www.gskforyou.com)) for more information on these programs. Alternatively, the GSK patient assistance program can be contacted at 1-800-745-2967, Monday through Friday from 8:30 AM to 8:00 PM (Eastern Time).

Questions should be directed to Provider Services at 1-800-835-4080.